Acciones Isodiol International Inc. Canadian Securities Exchange
Acciones
ISOL
CA46500L2003
Farmacéuticos
Ventas 2018 | 19,14 M 26,08 M 17,65 M | Ventas 2019 | 22,25 M 30,32 M 20,51 M | Capitalización | 49,96 M 68,07 M 46,06 M |
---|---|---|---|---|---|
Resultado Neto 2018 | -36 M -49,05 M -33,2 M | Resultado Neto 2019 | -126 M -172 M -116 M | VE / Ventas 2018 | 12,6 x |
Posición de caja neta 2018 | 15,55 M 21,19 M 14,34 M | Deuda neta 2019 | 5,22 M 7,12 M 4,82 M | VE / Ventas 2019 | 2,48 x |
P/E ratio 2018 |
-4,94
x | P/E ratio 2019 |
-0,37
x | Empleados | - |
Rendimiento 2018 * |
-
| Rendimiento 2019 |
-
| Flotante | 100 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24/05/17 |
Director/Board Member | - | 30/08/18 | |
Kevin Swadish
PRN | Corporate Officer/Principal | - | 14/02/19 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24/05/17 |
Director/Board Member | - | 30/08/18 | |
Director/Board Member | - | 21/11/18 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+37,29 % | 6020,86 M | |
-21,28 % | 4189,39 M | |
+4,52 % | 3254,87 M | |
-18,16 % | 2873,58 M | |
-7,70 % | 2374,9 M | |
+41,50 % | 1885,2 M | |
-4,05 % | 1579,81 M | |
-15,56 % | 1540,37 M | |
-14,62 % | 1501,64 M |